Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gunduz Eren, Ulas Turgay, Ozkalemkas Fahir, Toprak Selami Kocak, Karakulak Elifcan Aladag, Ar Muhlis Cem, Gulbas Zafer, Ozkocaman Vildan, Aydogan Merve, Buyukasik Yahya, Cerme Melis Dila Ozer, Mehtap Ozgur, Kucur Damlanur, Kaya Emin, Yavasoglu Irfan, Besisik Sevgi Kalayoglu, Ersal Tuba, Yuksel Merve, Hacioglu Sibel, Hacibekiroglu Tuba, Kaya Ahmet, Sakci Elif, Yuksel Meltem Kurt, Ozet Gulsum, Cagliyan Gulsum Akgun, Hasanzade Ulviyya, Salim Ozan, Pepeler Mehmet Sezgin, Turgut Mehmet, Kurekci Derya Deniz, Giden Asli Odabasi, Sener Seray, Calika Sinem, Dal Mehmet Sinan
Аннотация
Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis to first treatment was 119 ± 287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212 ± 321 days, and to Anti-Thymocyte Globulin (ATG) was 87 ± 242.5 days. The mean time to response after first-line and second-line treatment was 172.9 ± 264.6 days and 191.9 ± 211.9 days, respectively. The mean overall survival of patients with AA was 3.56 ± 3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to previous studies, providing vital insights into Turkiye's acquired AA treatment landscape.